The convergence of clinical and biomarker effects in a biomarker enriched subgroup in the Phase II ALS dataset with AP-101 is ...

The ALS therapy candidate AP-101 significantly extended patient survival and delayed the need for respiratory support in a ...

Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AP-101 is an investigational human-derived antibody therapeutic that selectively targets the misfolded ...

Misfolded proteins can gum up the cell’s works by glomming together and boosting inflammation. The cell, in turn, fights back by destroying the aggregated proteins. In the case of amyotrophic lateral ...

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

Mutations in copper-zinc superoxide dismutase 1 (SOD1) derail folding of the protein, preventing it from playing nice with its siblings. This leads the mutant down a path to aggregation and ...

Mutations in the gene SOD1 can cause the enzyme it encodes to fold in ways that are harmful to neurons—an abnormality that's responsible for about 20% of familial amyotrophic lateral sclerosis (ALS).

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neurofilament light chain and cerebrospinal fluid ...

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...

Amyloid Lateral Sclerosis (ALS), otherwise known as motor neuron disease (MND) or Lou Gehrig’s disease, is a neurodegenerative disorder leading to a loss of motor neurons and death, often caused by ...

Wild-type copper–zinc superoxide dismutase (SOD1) may cause sporadic amyotrophic lateral sclerosis (ALS) via a conformation and mechanism shared with mutant SOD1—a pathogenic factor in familial ...